CardioVascular BioTherapeutics (fka CVBT)

[johnnyblades2001]

Let's not forget the value of VT is in their patents.

20 patents across 7 clinical and pre-clinical indications. 4 pending related to COVID.

Remember when someone tried to convince everyone how useless biotech patents are?
Major Biotech companies disagree. 848 patents on 12 drugs. Twelve.

But who wants to talk about irrelevant Gary Spraker? Hahahahhaha

Personally I'm glad the current team knows what they are doing and protecting their IP with patents.

https://accessiblemeds.org/resources/blog/pharmaceutical-patent-abuse-infinity-and-beyond

We are, however, increasingly seeing evidence of how the patent system is being used to tip the balance and delay patient access to a point well beyond what Congress intended. In a recent report from I-MAK, the top 12 brand drugs on the market last year are protected by a total of 848 patents (71 per drug) providing an average of 38 years without generic competition. A few examples from the report:

The world’s top-selling brand drug, Humira, treats arthritis and other chronic conditions. On the market since 2002, 132 patents block competition for up to 39 years.
One of the most prescribed cancer treatments, Revlimid, was approved by the FDA in 2005. The patent thicket consists of 96 patents providing potentially 40 years without competition.
Diabetes patients who rely on the insulin treatment, Lantus, may not see a generic alternative for 37 years due to the 49 patents issued.
There is no question that several of these patents represent true innovation. New patient populations benefit from the same drug being used to treat a different condition, for example. But the expansive use of the patent system to build barriers to generic and biosimilar competition results in patients paying higher drug prices for longer.